Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 5Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic Adenocarcinoma 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Diseases 1Glioma 1Carcinoma, Transitional Cell 1Carcinoma 1Anus Neoplasms 1Advanced Solid Tumor, Adult 1Advanced Solid Tumor 1

Interventions

Injections 13toripalimab 12pembrolizumab 4atezolizumab 4Gemcitabine 4Carboplatin 4Cisplatin 3trastuzumab deruxtecan 2tislelizumab 2spartalizumab 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Albumin-Bound Paclitaxel 2talazoparib 1sintilimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1mirdametinib 1enfortumab vedotin 1conteltinib 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Letrozole 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumor × niraparib × Clear all
NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

LaNova Medicines Limited

Phase 1/2 Recruiting
320 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡